<DOC>
	<DOCNO>NCT00576823</DOCNO>
	<brief_summary>Primary objective determine efficacy Alfuzosin treatment child adolescents 2-16 year age newly diagnose progressive hydronephrosis due elevate detrusor Leak Point Pressure [ LPP ] neuropathic etiology . Secondary objective : - To investigate safety tolerability alfuzosin 0.2 mg/kg/day child adolescent , - To investigate number Urinary Tract Infection ( UTI ) episodes , - To investigate pharmacokinetics Alfuzosin ( population kinetics ) .</brief_summary>
	<brief_title>Alfuzosin Treatment Children Adolescents With Hydronephrosis Neuropathic Etiology</brief_title>
	<detailed_description>The study consist 2 phase : - 12-week efficacy phase , - 40-week safety extension phase . All eligible subject receive alfuzosin 0.2 mg/kg/day . The formulation frequency assign Interactive Voice Response System ( IVRS ) accord age group ability swallow tablet . Patients complete 12-week open-label treatment period offer continue 40-week open-label safety extension study . The treatment 12-week efficacy phase . All patient one-week follow-up period last dose intake .</detailed_description>
	<mesh_term>Urinary Bladder , Neurogenic</mesh_term>
	<mesh_term>Hydronephrosis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Alfuzosin</mesh_term>
	<criteria>Children adolescents either gender 2 16 year age detrusor Leak Point Pressure ( LPP ) 40 cm water great newly diagnose progressive hydronephrosis either Society Fetal Urology ( SFU ) grade 1 , 2 3 due neuropathic bladder dysfunction . Hydronephrosis nonneuropathic etiology . Urological surgery last 4 month prior study . Urethral dilatation last 3 month prior baseline urodynamic assessment . αblocker therapy last 4 week prior baseline urodynamic assessment . Detrusor injection botulinum toxin last 6 month . Urological diseases/conditions functional bladder obstruction neuropathic etiology , lead upper urinary tract dilatation ( e.g. , bladder anomaly , ureterocele ) . History intolerance αblocker therapy . Orthostatic hypotension . History risk factor Torsade de pointes ( e.g. , family history Long QT Syndrome ) . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>child</keyword>
	<keyword>bladder</keyword>
	<keyword>neuropathic</keyword>
	<keyword>alpha blocker</keyword>
</DOC>